Citigroup Inc Precigen, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Precigen, Inc. stock. As of the latest transaction made, Citigroup Inc holds 97,578 shares of PGEN stock, worth $73,183. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,578

Previous 34,032 186.72%

Holding current value

$73,183

Previous $53,000 73.58%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.91 - $1.88 $57,826 - $119,466	63,546 Added 186.72%	97,578 $92,000
Q2 2024 Aug 12, 2024	BUY	$1.27 - $1.75 $10,605 - $14,614	8,351 Added 32.52%	34,032 $53,000
Q1 2024 May 10, 2024	BUY	$1.21 - $1.75 $3,160 - $4,571	2,612 Added 11.32%	25,681 $37,000
Q4 2023 Feb 09, 2024	BUY	$0.89 - $1.41 $17,630 - $27,932	19,810 Added 607.86%	23,069 $30,000
Q3 2023 Nov 09, 2023	SELL	$1.08 - $1.85 $44,614 - $76,423	-41,310 Reduced 92.69%	3,259 $4,000
Q2 2023 Aug 10, 2023	BUY	$0.96 - $1.4 $9,746 - $14,214	10,153 Added 29.5%	44,569 $51,000
Q1 2023 May 11, 2023	SELL	$0.88 - $2.19 $7,368 - $18,336	-8,373 Reduced 19.57%	34,416 $36,000
Q4 2022 Feb 09, 2023	SELL	$1.27 - $2.26 $12,367 - $22,007	-9,738 Reduced 18.54%	42,789 $65,000
Q3 2022 Nov 10, 2022	SELL	$1.41 - $2.79 $12,773 - $25,274	-9,059 Reduced 14.71%	52,527 $111,000
Q2 2022 Aug 10, 2022	SELL	$1.15 - $2.53 $41,610 - $91,542	-36,183 Reduced 37.01%	61,586 $83,000
Q1 2022 May 12, 2022	SELL	$1.91 - $3.98 $746,827 - $1.56 Million	-391,009 Reduced 80.0%	97,769 $207,000
Q4 2021 Feb 10, 2022	BUY	$3.53 - $5.5 $857,991 - $1.34 Million	243,057 Added 98.92%	488,778 $1.81 Million
Q3 2021 Nov 10, 2021	BUY	$4.99 - $6.55 $1.23 Million - $1.61 Million	245,721 New	245,721 $1.23 Million

Others Institutions Holding PGEN

# of Institutions

143

Shares Held

159M

Call Options Held

232K

Put Options Held

69K

View Full List

About PRECIGEN, INC.

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $156M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

More about PGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account